Doc's Attys Duel Over Fee Split In $785M Pfizer FCA Deal
By Dani Kass · January 8, 2018, 8:35 PM EST
Three firms that represented a whistleblower in a False Claims Act suit against a Pfizer subsidiary on Monday set the stage for an upcoming civil trial over fees with briefs disputing...
To view the full article, register now.